 |
|
|
|
|
| Dosing |
| |
The recommended dosage of Kepivance® is 60 mcg/kg/d,
administered as an IV bolus injection for 3 consecutive days before and 3 consecutive
days after myelotoxic chemotherapy and/or TBI for a total of 6 doses.1
The first 3 doses
should be administered prior to
myelotoxic therapy, with the
third dose 24 to 48 hours before myelotoxic therapy.1
The last 3 doses
should be administered post
myelotoxic therapy; the first of
these doses should be administered after,
but on the same day of hematopoietic
stem cell infusion and at least 4 days
after the most recent Kepivance® administration
(Figure 1).1
Kepivance® should not be administered within 24 hours before, during infusion of, or within
24 hours after administration of myelotoxic chemotherapy. In a clinical trial, administration of Kepivance®
within 24 hours of chemotherapy resulted in increased severity and duration of oral mucositis.1
Figure 1. Kepivance® Dosing Schedule1
3 consecutive single
IV bolus doses |
|
3 consecutive single
IV bolus doses |
| BEFORE HSCT |
AFTER HSCT |
| 60 mcg/kg/day |
60 mcg/kg/day |
| |
|
|
Dose
1 |
Dose
2 |
Dose
3 |
|
|
Dose
4 |
Dose
5 |
Dose
6 |
| |
24 to 48 hours before myelotoxic regimen |
Length of time
may vary |
24 hours
after
myelotoxic
regimen |
DAY 0
After
HSCT
infusion and
at least
4 days after
dose 3 |
|
|
|
Adapted from Kepivance® prescribing information.
If heparin is used to maintain an IV line, saline
should be used to rinse the line prior to and after Kepivance® administration, since Kepivance® has
been shown to bind to heparin in vitro.1
| 1 |
Kepivance® (palifermin) prescribing information. |
 Back to top
ABOUT ORAL MUCOSITIS
ABOUT KEPIVANCE®
TOOLS AND RESOURCES
FOR NURSES
FOR PHARMACISTS
IMPORTANT PRODUCT SAFETY INFORMATION
|
 |
|
| |
|
|
|
|
|
